Key result
Conventional chemotherapy with doxorubicin and ifosfamide remains the mainstay of systemic treatment for liposarcoma, with novel targets like MDM2 and CDK4 currently in early-phase trials.
This review summarizes current and emerging systemic treatment options for liposarcoma, highlighting the ongoing need for novel therapies beyond conventional chemotherapy.
No takes yet. Share an insight, caveat, or question.
Current standard remains doxorubicin and ifosfamide for liposarcoma; leaves open efficacy of MDM2/CDK4 agents pending later-phase trials.
Kollár et al. (2014) conducted a review in Liposarcoma. Systemic treatment options was evaluated. Conventional chemotherapy with doxorubicin and ifosfamide remains the mainstay of systemic treatment for liposarcoma, with novel targets like MDM2 and CDK4 currently in early-phase trials.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: